K D Quinn1,2, M Schedel3, Y Nkrumah-Elie1, A Joetham3, M Armstrong1, C Cruickshank-Quinn1, R Reisdorph1, E W Gelfand3, N Reisdorph1,2. 1. School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO, USA. 2. Immunology & Microbiology Department School of Medicine, University of Colorado Denver, Aurora, CO, USA. 3. Division of Cell Biology, Department of Pediatrics, National Jewish Health, Denver, CO, USA.
Abstract
BACKGROUND: Asthma is a complex lung disease resulting from the interplay of genetic and environmental factors. To understand the molecular changes that occur during the development of allergic asthma without genetic and environmental confounders, an experimental model of allergic asthma in mice was used. Our goals were to (1) identify changes at the small molecule level due to allergen exposure, (2) determine perturbed pathways due to disease, and (3) determine whether small molecule changes correlate with lung function. METHODS: In this experimental model of allergic asthma, matched bronchoalveolar lavage (BAL) fluid and plasma were collected from three groups of C57BL6 mice (control vs sensitized and/or challenged with ovalbumin, n=3-5/group) 6 hour, 24 hour, and 48 hour after the last challenge. Samples were analyzed using liquid chromatography-mass spectrometry-based metabolomics. Airway hyper-responsiveness (AHR) measurements and differential cell counts were performed. RESULTS: In total, 398 and 368 dysregulated metabolites in the BAL fluid and plasma of sensitized and challenged mice were identified, respectively. These belonged to four, interconnected pathways relevant to asthma pathogenesis: sphingolipid metabolism (P=6.6×10-5 ), arginine and proline metabolism (P=1.12×10-7 ), glycerophospholipid metabolism (P=1.3×10-10 ), and the neurotrophin signaling pathway (P=7.0×10-6 ). Furthermore, within the arginine and proline metabolism pathway, a positive correlation between urea-1-carboxylate and AHR was observed in plasma metabolites, while ornithine revealed a reciprocal effect. In addition, agmatine positively correlated with lung eosinophilia. CONCLUSION: These findings point to potential targets and pathways that may be central to asthma pathogenesis and can serve as novel therapeutic targets.
BACKGROUND: Asthma is a complex lung disease resulting from the interplay of genetic and environmental factors. To understand the molecular changes that occur during the development of allergic asthma without genetic and environmental confounders, an experimental model of allergic asthma in mice was used. Our goals were to (1) identify changes at the small molecule level due to allergen exposure, (2) determine perturbed pathways due to disease, and (3) determine whether small molecule changes correlate with lung function. METHODS: In this experimental model of allergic asthma, matched bronchoalveolar lavage (BAL) fluid and plasma were collected from three groups of C57BL6 mice (control vs sensitized and/or challenged with ovalbumin, n=3-5/group) 6 hour, 24 hour, and 48 hour after the last challenge. Samples were analyzed using liquid chromatography-mass spectrometry-based metabolomics. Airway hyper-responsiveness (AHR) measurements and differential cell counts were performed. RESULTS: In total, 398 and 368 dysregulated metabolites in the BAL fluid and plasma of sensitized and challenged mice were identified, respectively. These belonged to four, interconnected pathways relevant to asthma pathogenesis: sphingolipid metabolism (P=6.6×10-5 ), arginine and proline metabolism (P=1.12×10-7 ), glycerophospholipid metabolism (P=1.3×10-10 ), and the neurotrophin signaling pathway (P=7.0×10-6 ). Furthermore, within the arginine and proline metabolism pathway, a positive correlation between urea-1-carboxylate and AHR was observed in plasma metabolites, while ornithine revealed a reciprocal effect. In addition, agmatine positively correlated with lung eosinophilia. CONCLUSION: These findings point to potential targets and pathways that may be central to asthma pathogenesis and can serve as novel therapeutic targets.
Authors: Joel Andrew Mathews; David Itiro Kasahara; Youngji Cho; Lauren Nicole Bell; Philip Ross Gunst; Edward D Karoly; Stephanie Ann Shore Journal: PLoS One Date: 2017-07-13 Impact factor: 3.240
Authors: Scott Walmsley; Charmion Cruickshank-Quinn; Kevin Quinn; Xing Zhang; Irina Petrache; Russell P Bowler; Richard Reisdorph; Nichole Reisdorph Journal: Sci Data Date: 2018-04-17 Impact factor: 6.444
Authors: Anandita Pal; Abrar E Al-Shaer; William Guesdon; Maria J Torres; Michael Armstrong; Kevin Quinn; Traci Davis; Nichole Reisdorph; P Darrell Neufer; Espen E Spangenburg; Ian Carroll; Richard P Bazinet; Ganesh V Halade; Joan Clària; Saame Raza Shaikh Journal: FASEB J Date: 2020-06-24 Impact factor: 5.191
Authors: Priyadarshini Kachroo; Joanne E Sordillo; Sharon M Lutz; Scott T Weiss; Rachel S Kelly; Michael J McGeachie; Ann Chen Wu; Jessica A Lasky-Su Journal: J Pers Med Date: 2021-11-04
Authors: Ying Liu; Jing Zheng; Hong Ping Zhang; Xin Zhang; Lei Wang; Lisa Wood; Gang Wang Journal: Allergy Asthma Immunol Res Date: 2018-11 Impact factor: 5.764